Skip to content

Dietary Sodium Restriction in Renal Transplant Recipients.

Dietary Sodium Restriction in Renal Transplant Recipients: An intervention study to investigate the effects of dietary sodium restriction on blood pressure.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22929
Enrollment
42
Registered
2013-04-13
Start date
2012-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation

Interventions

Low dietary sodium intake (~50 mmol/day = 3 grams salt/day) vs liberal dietary sodium intake (~150 mmol/dayg = 9 grams salt/day). This is a crossover design with an intervention period of 6 weeks each

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Written informed consent; 2. Male and female transplant recipients; 3. Transplantation performed in the University Medical Center Groningen or Academic Medical Center Amsterdam; 4. Patients that are one year after transplantation or beyond; 5. 18 years or older; 6. Stable renal function at study entry; 7. Use of RAAS-blockade: either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB).

Exclusion criteria

Exclusion criteria: 1. Blood pressure 160/95 mmHg; 3. Complaints or signs of orthostatic hypotension; 4. Creatinine clearance 1.5 g/24h; 6. Being on a cyclosporine withdrawal regimen; 7. Rejection of the allograft for which a switch in immunosuppressive medication is necessary; 8. Severe general diseases or mental disorders making the participation in the study impossible; 9. Pregnancy; 10. Drug abuse; 11. No sufficient knowledge of the Dutch language to participate in the study; 12. Participation in another intervention study during or within a month prior to this study.

Design outcomes

Primary

MeasureTime frame
1. Blood pressure; 2. Number of antihypertensives used.

Secondary

MeasureTime frame
1. Extracellular volume, as measured by volume marker NT-proBNP; 2. Renal damage, as measured by urinary protein/albumin excretion, and urinary excretion of tubulointerstitial damage markers.

Contacts

Public ContactL.V. Vries, de

Hanzeplein 1

l.v.de.vries@umcg.nl+31 (0)50 3615839

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)